You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 151 No. 2, FEBRUARY 1991 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (26)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Increased Serum Aluminum

An Independent Risk Factor for Mortality in Patients Undergoing Long-term Hemodialysis

Joseph A. Chazan, MD; Nancy L. Lew, SM; Edmund G. Lowrie, MD

Arch Intern Med. 1991;151(2):319-322.


Abstract



The annual mortality rate among patients receiving long-term hemodialysis has been rising over the past decade. The prevalences of known risk factors such as older age, male sex, duration of dialysis, presence of diabetes, coronary artery disease, or hypertension do not seem to have changed during this time. However, evidence suggests that an increased body aluminum level may have an adverse effect on survival even in the absence of overt aluminum toxic reaction. Therefore, we evaluated the correlation between serum aluminum levels and mortality in 10 646 patients undergoing long-term hemodialysis. Mortallities were 18% higher for patients with serum aluminum levels between 1520 and 2220 nmol/L and progressively increased to 60% higher for patients with aluminum levels above 7410 nmol/L. Serum aluminum level was an important predictor of survival even after other known risk factors had been controlled. These data strongly suggest that patients undergoing long-term hemodialysis should have periodic surveillance of the serum aluminum levels, and in those patients who have plasma levels of 1520 to 2220 nmol/L or higher, one should seriously consider discontinuing aluminum salts and giving therapy to decrease body aluminum level if it is found to be increased.

(Arch Intern Med. 1991;151:319-322)



Author Affiliations



From the Division of Renal Diseases, Department of Medicine, Rhode Island Hospital, and the Division of Biological and Medical Sciences, Brown University, Providence, RI (Dr Chazan); and National Medical Care, Inc, Waltham, Mass (Ms Lew and Dr Lowrie).


Footnotes



Accepted for publication July 31, 1990.

Presented in part at the 22nd Annual Meeting of the American Society of Nephrology, Washington, DC, December 3, 1989.

Reprint requests to Division of Renal Diseases, Rhode Island Hospital, Providence, RI02903 (Dr Chazan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature
Johnson et al.
Nephrol Dial Transplant 1999;14:2156-2164.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.